Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of MDG1015 in selected solid tumors
NL-OMON59520Phase 1Not yet recruiting
- Sponsor
- Medigene AG
- Start
- Apr 2025
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 1, single-arm trial of MDG1015 in epithelial ovarian cancer (EOC), gastroesophageal junction adenocarcinoma, Myxoid/round cell liposarcoma (MRCLS) and 1 more, sponsored by Medigene AG. Primary endpoint: Safety and tolerability. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
MDG1015
03
Conditions
epithelial ovarian cancer (EOC)gastroesophageal junction adenocarcinomaMyxoid/round cell liposarcoma (MRCLS)synovial sarcoma (SS)
Beyond the preview
Go deeper on NL-OMON59520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59520.